特异性免疫治疗对慢性荨麻疹患者临床及外周血IL-4和sVCAM-1水平的影响  

The Effect of Specific Immunotherapy to Clinical Score and the Serum Levels of IL-4 and sVCAM-1 in Chronic Urticaria Patients

作　　者：董萍云[1] 魏春波[1] 王莹莹[1] 荣在丽[1] 

机构地区：[1]河北医科大学第二医院皮肤性病科,河北石家庄050000

出　　处：《中国皮肤性病学杂志》2005年第11期674-675,共2页The Chinese Journal of Dermatovenereology

摘　　要：目的探讨特异性免疫治疗对慢性荨麻疹患者的疗效和作用机理。方法对30例吸入组皮肤试验阳性的慢性荨麻疹患者进行特异性免疫治疗并观察疗效,用ELISA法检测患者治疗前后及健康对照组IL-4和sVCAM-1的血清水平。结果病例组经特异性免疫治疗3个疗程,有效率83.33%。病例组治疗前IL-4和sVCAM-1血清浓度明显高于对照组(P<0.05和0.01),经特异性免疫治疗后浓度下降,较治疗前均有显著差异(P<0.01和0.001)。sVCAM-1与IL-4血清浓度无直线相关关系(r=0.0268,P>0.05)。结论特异性免疫治疗对慢性荨麻疹患者安全有效。IL-4和sV-CAM-1可作为监测慢性荨麻疹病情变化指标之一。特异性免疫治疗可能是通过免疫调节达到其治疗作用。Objective To explore the mechanism and efficacy of specific immunotherapy in chronic urticaria. Methods We treated thirty chronic urticaria patients by specific immunotherapy, then observed the effect and measured serum levels of IL-4 and sVCAM-1 before and after treatment in patients and normal controls by ELISA. Results The effective rate was 83.33%. The serum levels of IL-4 and sVCAM-1 in chronic urticaria patients were significantly increased compared to that of the normal controls （ P 〈0.05 and 0.01 ） , After treatment, the serum level of IL-4 and sVCAM-1 in chronic urticaria patients decreased significantly （P 〈0.01 aud 0. 001 ）. In chronic .urticaria patients,there was no significant correlation between the serum level of sVCAM-1 and IL-4. Conclusion Specific immunotherapy is an effective anti safe treatment in chronic urticaria. IL-4 and sVCAM-1 may he used as a .taker for monitoring disease activity and response to treatment in chronic urticaria. Specific immunotherapy maybe make role by modulating the function of immune system.

关 键 词：慢性荨麻疹 特异性免疫治疗 白介素-4 可溶性血管内皮细胞黏附分子-1 

分 类 号：R758.24[医药卫生—皮肤病学与性病学]